News

FDA approves first generic form of oxiconazole nitrate cream


 

References

A generic formulation of oxiconazole nitrate cream, 1% has been approved by the Food and Drug Administration, for the treatment of tinea pedis, tinea cruris, tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes, or Epidermophyton floccosum) and tinea (pityriasis) versicolor due to Malassezia furfur.

This is the first generic version of Oxistat to be approved, according to the FDA’s statement announcing the approval.

The label for the generic, manufactured by Taro Pharmaceuticals U.S.A. is available here.

emechcatie@frontlinemedcom.com

Recommended Reading

Study: Two varicella vaccination doses more effective than one
MDedge Pediatrics
Infection rates similar for in- and out-of-hospital pediatric cardiac arrest
MDedge Pediatrics
X-Linked Adrenoleukodystrophy and Mucopolysaccharidosis Type I added to Recommended Uniform Newborn Screening Panel
MDedge Pediatrics
Severe dengue fever outcomes predicted via metabolomics
MDedge Pediatrics
Flu activity reaches another new season high
MDedge Pediatrics
Flu vaccination found safe in surgical patients
MDedge Pediatrics
As varicella recedes, zoster rises: The question is ‘why?’
MDedge Pediatrics
HPV vaccination protects high-risk girls from cervical cancer
MDedge Pediatrics
Among recent U.S. measles patients, 42% intentionally unvaccinated
MDedge Pediatrics
Study links microcephaly to first trimester Zika infection
MDedge Pediatrics